AtaiBeckley Inc. Gains Bullish Support from H.C. Wainwright
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Should l Buy ATAI?
Source: Yahoo Finance
- Clinical Data Support: AtaiBeckley Inc.'s recent Phase 2a data for BPL-003 indicates that a single dose produces significant therapeutic effects lasting over 12 weeks, enhancing market confidence in its competitive position within the 5-MeO-DMT class and boosting investor sentiment.
- Price Target Reaffirmed: H.C. Wainwright reaffirmed its 'Buy' rating and set a price target of $25.00 on March 17, 2026, indicating substantial upside from the current level of $3.65, reflecting analysts' optimistic outlook on the company's future performance.
- FDA Trial Design Agreement: AtaiBeckley reached an agreement with the FDA on the dual-trial design for its planned Phase 3 program, ensuring the project is on track for launch in Q2 2026, further solidifying its leadership in the mental health treatment space.
- Breakthrough Therapy Designation: BPL-003 received Breakthrough Therapy designation in October 2025, with CEO Srinivas Rao highlighting its rapid and durable antidepressant effects, suggesting its potential to reshape the treatment landscape for treatment-resistant depression.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ATAI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ATAI
Wall Street analysts forecast ATAI stock price to rise
7 Analyst Rating
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 3.350
Low
10.00
Averages
13.00
High
16.00
Current: 3.350
Low
10.00
Averages
13.00
High
16.00
About ATAI
AtaiBeckley Inc is a clinical-stage biotechnology company focused on developing rapid-acting, durable and convenient mental health treatments. The Company’s pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 (R-MDMA HCI) for social anxiety disorder. The Company is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for opioid use disorder and TRD. BPL-003 is a proprietary synthetic intranasal formulation of mebufotenin benzoate being developed as a potential treatment for people living with TRD. VLS-01 is a proprietary oral transmucosal film formulation of N,N-Dimethyltryptamine (DMT) being developed as a potential treatment for people living with TRD. EMP-01 is an oral formulation of R-MDMA, being developed as a potential treatment for people living with social anxiety disorder.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Deutsche Bank Sees AtaiBeckley as a Leader in Psychedelic Renaissance
- Positive Market Outlook: Deutsche Bank initiated coverage on AtaiBeckley with a buy rating and a $12 price target, indicating over a 250% upside from Friday's close, reflecting strong market confidence in its position within the psychedelic drug sector.
- Drug Development Potential: AtaiBeckley is developing two key drugs for treatment-resistant depression, BPL-003 and VLS-01, with potential U.S. sales peaking at $4 billion and $2 billion respectively, highlighting significant market opportunities for its product pipeline.
- Increased Industry Recognition: As psychedelic therapies gain popularity in mental health treatment, Deutsche Bank's analyst noted that AtaiBeckley has emerged as a bona fide drug developer, attracting interest from investors typically focused on conventional therapeutics, underscoring its leadership in this nascent market.
- FDA Regulatory Changes: Hoang mentioned that the FDA's skepticism towards psychedelic therapies has eased, with expectations that upon FDA approval, these drugs will undergo federal rescheduling within 90 days, further enhancing market acceptance and investor confidence.
See More
Wall Street's Latest Ratings Overview
- Honeywell Upgrade: BMO has upgraded Honeywell to Outperform, citing additional opportunities through the end of the decade; despite lagging shares, the company's strong balance sheet provides downside protection and supports upcoming spin-offs.
- Disney Outlook: Wells Fargo reiterates Disney as Overweight, lowering its price target to $148 but highlighting the new leadership team's potential to revitalize the narrative, making Q2 a pivotal moment for growth acceleration.
- Knight-Swift Upgrade: Evercore ISI has upgraded Knight-Swift to Outperform, viewing the transport company as compelling due to its leverage to improving fundamentals, while trading at one of the lowest multiples in its peer group.
- FuboTV Initiation: B Riley initiates coverage of FuboTV with a Buy rating and a target price of $18, emphasizing the stock's undervaluation and its potential in the consumer live television streaming market.
See More
ATAIBECKLEY INC: DEUTSCHE BANK STARTS COVERAGE WITH A BUY RATING AND A TARGET PRICE OF $12
- Company Overview: AIBEKLEY INC is initiating coverage on Deutsche Bank.
- Investment Recommendation: The firm has issued a buy rating with a target price set at $12.
See More
AtaiBeckley Inc. Gains Bullish Support from H.C. Wainwright
- Clinical Data Support: AtaiBeckley Inc.'s recent Phase 2a data for BPL-003 indicates that a single dose produces significant therapeutic effects lasting over 12 weeks, enhancing market confidence in its competitive position within the 5-MeO-DMT class and boosting investor sentiment.
- Price Target Reaffirmed: H.C. Wainwright reaffirmed its 'Buy' rating and set a price target of $25.00 on March 17, 2026, indicating substantial upside from the current level of $3.65, reflecting analysts' optimistic outlook on the company's future performance.
- FDA Trial Design Agreement: AtaiBeckley reached an agreement with the FDA on the dual-trial design for its planned Phase 3 program, ensuring the project is on track for launch in Q2 2026, further solidifying its leadership in the mental health treatment space.
- Breakthrough Therapy Designation: BPL-003 received Breakthrough Therapy designation in October 2025, with CEO Srinivas Rao highlighting its rapid and durable antidepressant effects, suggesting its potential to reshape the treatment landscape for treatment-resistant depression.
See More
AtaiBeckley Reports Positive Phase 2a Results for BPL-003 in Treatment-Resistant Depression
- Clinical Trial Results: AtaiBeckley's BPL-003 (mebufotenin benzoate nasal spray) demonstrated significant antidepressant effects in a 12-week open-label trial involving 12 patients, with a single 10 mg dose leading to a 12.6-point reduction in the Montgomery–Åsberg Depression Rating Scale (MADRS) total score by day 2, maintained at a mean score of 14.5 by day 85, indicating long-term efficacy.
- Restoration of Pleasure: The mean Snaith-Hamilton Pleasure Scale (SHAPS) scores improved from a baseline of 8.4 to 1.5 by day 85, indicating the absence of anhedonia and further validating the effectiveness of BPL-003 in enhancing patients' quality of life.
- Good Safety Profile: Throughout the trial, BPL-003 was well tolerated with no serious adverse events reported, underscoring the drug's safety in treating patients with treatment-resistant depression.
- Future Plans: AtaiBeckley is on track to initiate a phase 3 program for BPL-003 in Q2, reflecting the company's optimistic outlook on the drug's development and potential market introduction.
See More
Atai Beckley Analysts Maintain Buy Ratings with $14 Price Target
- Investor Event Insights: Atai Beckley's investor event featured discussions by KOLs on BPL-003 and the treatment-resistant depression landscape, with analyst Ami Fadia highlighting key advantages such as durability of efficacy and improved safety compared to existing standards of care.
- Pricing Potential Analysis: Management sees potential for premium pricing above Spravato’s $60-65K annual cost based on BPL-003’s profile, which could significantly enhance the company's revenue potential in the mental health market.
- Clinical Trial Progress: Canaccord Genuity analyst Sumant Kulkarni noted that BPL-003 is on the verge of entering a Phase 3 program for treatment-resistant depression, with top-line readouts expected by early 2029, laying a solid foundation for the company's future market performance.
- Market Opportunity Assessment: Although data is not yet available, the investor day made a compelling case for BPL-003 as a potentially game-changing option for treatment-resistant depression patients, with analysts believing the stock is significantly undervalued relative to the market opportunity in mental health-focused indications.
See More
Deutsche Bank Sees AtaiBeckley as a Leader in Psychedelic Renaissance
- Positive Market Outlook: Deutsche Bank initiated coverage on AtaiBeckley with a buy rating and a $12 price target, indicating over a 250% upside from Friday's close, reflecting strong market confidence in its position within the psychedelic drug sector.
- Drug Development Potential: AtaiBeckley is developing two key drugs for treatment-resistant depression, BPL-003 and VLS-01, with potential U.S. sales peaking at $4 billion and $2 billion respectively, highlighting significant market opportunities for its product pipeline.
- Increased Industry Recognition: As psychedelic therapies gain popularity in mental health treatment, Deutsche Bank's analyst noted that AtaiBeckley has emerged as a bona fide drug developer, attracting interest from investors typically focused on conventional therapeutics, underscoring its leadership in this nascent market.
- FDA Regulatory Changes: Hoang mentioned that the FDA's skepticism towards psychedelic therapies has eased, with expectations that upon FDA approval, these drugs will undergo federal rescheduling within 90 days, further enhancing market acceptance and investor confidence.
See More
Wall Street's Latest Ratings Overview
- Honeywell Upgrade: BMO has upgraded Honeywell to Outperform, citing additional opportunities through the end of the decade; despite lagging shares, the company's strong balance sheet provides downside protection and supports upcoming spin-offs.
- Disney Outlook: Wells Fargo reiterates Disney as Overweight, lowering its price target to $148 but highlighting the new leadership team's potential to revitalize the narrative, making Q2 a pivotal moment for growth acceleration.
- Knight-Swift Upgrade: Evercore ISI has upgraded Knight-Swift to Outperform, viewing the transport company as compelling due to its leverage to improving fundamentals, while trading at one of the lowest multiples in its peer group.
- FuboTV Initiation: B Riley initiates coverage of FuboTV with a Buy rating and a target price of $18, emphasizing the stock's undervaluation and its potential in the consumer live television streaming market.
See More
ATAIBECKLEY INC: DEUTSCHE BANK STARTS COVERAGE WITH A BUY RATING AND A TARGET PRICE OF $12
- Company Overview: AIBEKLEY INC is initiating coverage on Deutsche Bank.
- Investment Recommendation: The firm has issued a buy rating with a target price set at $12.
See More
AtaiBeckley Inc. Gains Bullish Support from H.C. Wainwright
- Clinical Data Support: AtaiBeckley Inc.'s recent Phase 2a data for BPL-003 indicates that a single dose produces significant therapeutic effects lasting over 12 weeks, enhancing market confidence in its competitive position within the 5-MeO-DMT class and boosting investor sentiment.
- Price Target Reaffirmed: H.C. Wainwright reaffirmed its 'Buy' rating and set a price target of $25.00 on March 17, 2026, indicating substantial upside from the current level of $3.65, reflecting analysts' optimistic outlook on the company's future performance.
- FDA Trial Design Agreement: AtaiBeckley reached an agreement with the FDA on the dual-trial design for its planned Phase 3 program, ensuring the project is on track for launch in Q2 2026, further solidifying its leadership in the mental health treatment space.
- Breakthrough Therapy Designation: BPL-003 received Breakthrough Therapy designation in October 2025, with CEO Srinivas Rao highlighting its rapid and durable antidepressant effects, suggesting its potential to reshape the treatment landscape for treatment-resistant depression.
See More
AtaiBeckley Reports Positive Phase 2a Results for BPL-003 in Treatment-Resistant Depression
- Clinical Trial Results: AtaiBeckley's BPL-003 (mebufotenin benzoate nasal spray) demonstrated significant antidepressant effects in a 12-week open-label trial involving 12 patients, with a single 10 mg dose leading to a 12.6-point reduction in the Montgomery–Åsberg Depression Rating Scale (MADRS) total score by day 2, maintained at a mean score of 14.5 by day 85, indicating long-term efficacy.
- Restoration of Pleasure: The mean Snaith-Hamilton Pleasure Scale (SHAPS) scores improved from a baseline of 8.4 to 1.5 by day 85, indicating the absence of anhedonia and further validating the effectiveness of BPL-003 in enhancing patients' quality of life.
- Good Safety Profile: Throughout the trial, BPL-003 was well tolerated with no serious adverse events reported, underscoring the drug's safety in treating patients with treatment-resistant depression.
- Future Plans: AtaiBeckley is on track to initiate a phase 3 program for BPL-003 in Q2, reflecting the company's optimistic outlook on the drug's development and potential market introduction.
See More
Atai Beckley Analysts Maintain Buy Ratings with $14 Price Target
- Investor Event Insights: Atai Beckley's investor event featured discussions by KOLs on BPL-003 and the treatment-resistant depression landscape, with analyst Ami Fadia highlighting key advantages such as durability of efficacy and improved safety compared to existing standards of care.
- Pricing Potential Analysis: Management sees potential for premium pricing above Spravato’s $60-65K annual cost based on BPL-003’s profile, which could significantly enhance the company's revenue potential in the mental health market.
- Clinical Trial Progress: Canaccord Genuity analyst Sumant Kulkarni noted that BPL-003 is on the verge of entering a Phase 3 program for treatment-resistant depression, with top-line readouts expected by early 2029, laying a solid foundation for the company's future market performance.
- Market Opportunity Assessment: Although data is not yet available, the investor day made a compelling case for BPL-003 as a potentially game-changing option for treatment-resistant depression patients, with analysts believing the stock is significantly undervalued relative to the market opportunity in mental health-focused indications.
See More
